ACHFF

Quote

Short

News

Articles

Message Board

Arch Biopartners Inc. (OTCMKTS : ACHFF ) News

News Releases

ACHFF News Releases

July 17, 2026 08:20:00 am

GlobeNewswire

Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program

June 04, 2026 07:41:08 am

GlobeNewswire

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

May 22, 2026 06:50:00 am

GlobeNewswire

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

April 30, 2026 07:00:00 am

GlobeNewswire

Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI

March 24, 2026 09:13:43 am

GlobeNewswire

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

March 20, 2026 07:05:00 am

GlobeNewswire

Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

February 09, 2026 07:28:52 am

GlobeNewswire

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

January 16, 2026 08:15:00 am

GlobeNewswire

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

December 16, 2025 07:40:00 am

GlobeNewswire

Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

November 19, 2025 04:27:50 pm

GlobeNewswire

Arch Biopartners Closes Non-Brokered Private Placement

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account